Clindamycin Pledget

Name: Clindamycin Pledget

Indications and Usage for Clindamycin Pledget

Clindamycin Phosphate Topical Solution USP, 1% is indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate (see CONTRAINDICATIONS, WARNINGS and ADVERSE REACTIONS).

Contraindications

Clindamycin Phosphate Topical Solution USP, 1% is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.

Adverse Reactions

In 18 clinical studies of various formulations of topical clindamycin phosphate using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatologic events [see table below].

Number of Patients Reporting Events

Treatment Emergent

Solution

Gel

Lotion

Adverse Event

n=553 (%)

n=148(%)

n=160(%)

Burning

62 (11)

15 (10)

17 (11)

Itching

36 (7)

15 (10)

17 (11)

Burning/Itching

60 (11)

# (-)

# (-)

Dryness

105 (19)

34 (23)

29 (18)

Erythema

86 (16)

10 (7)

22 (14)

Oiliness/Oily Skin

8 (1)

26 (18)

12* (10)

Peeling

61 (11)

# (-)

11 (7)

# not recorded

* of 126 subjects

Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally. Cases of diarrhea, bloody diarrhea and colitis (including pseudomembranous colitis) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin (see WARNINGS).

Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin.

Clindamycin Pledget Dosage and Administration

Do not use if the seal on jar is broken. Remove pledget from jar just before use. Use a pledget to apply a thin film of Clindamycin Phosphate Topical Solution to the affected area twice daily. More than one pledget may be used. Each pledget should be used only once and then discarded. Keep jar tightly closed when not in use. (Jar Configuration)

Do not use if the unit-dose pouch seal is broken. Remove pledget just before use. Use pledget to apply a thin film of Clindamycin Phosphate Topical Solution to the affected area twice daily. More than one pledget may be used. Each pledget should be used only once and then discarded. (Individually Wrapped Pledget Configuration)

Storage

Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. Protect from freezing.

Manufactured By

Perrigo

Bronx, NY 10457

Distributed By Perrigo

Allegan, MI 49010

www.perrigo.com

:0T900 RC J6 (Perrigo part number for jar configuration insert)

:0T900 RC J7 (Perrigo part number for Individually Wrapped Pledget configuration insert)

Rev 02-16

Principal Display Panel

Clindamycin Phosphate Topical Solution USP, Pledget 1%*

*equivalent to 1% (10 mg/mL) clindamycin

For Topical Use Only.

60 Pledgets

Rx Only

CLINDAMYCIN PHOSPHATE 
clindamycin phosphate solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:45802-263
Route of Administration TOPICAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Clindamycin Phosphate (Clindamycin) Clindamycin 10 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
Isopropyl Alcohol  
Propylene glycol  
Sodium Hydroxide  
Water  
Packaging
# Item Code Package Description
1 NDC:45802-263-37 60 APPLICATOR in 1 JAR
1 1 mL in 1 APPLICATOR
2 NDC:45802-263-93 69 APPLICATOR in 1 JAR
2 1 mL in 1 APPLICATOR
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA065049 05/31/2006
Labeler - Perrigo New York Inc (078846912)
Revised: 01/2017   Perrigo New York Inc
(web3)